FDA clears Biolinq Shine glucose sensor for over-the-counter use

On September 18, 2026, the FDA cleared the Biolinq Shine Autonomous Time-in-Range Microsensor for over-the-counter use, so no prescription is needed.[1] Biolinq announced the clearance on September 24 and said it expands access to Biolinq Shine without a prescription.[2]

What the FDA cleared

The clearance is numbered K262599. The FDA received the 510(k) submission on July 27. Less than two months later it recorded its decision as "Substantially Equivalent."[3] The letter places the device in Class II as a glucose range monitoring system.[1]

The predicate, meaning the already-authorized device it was compared with, is Biolinq's own earlier version of Shine.[1] The FDA granted that version through the De Novo pathway, used for new kinds of devices with no existing match, on September 23, 2025.[4] The 510(k) summary says the device itself and its sensing method did not change. The changes were limited to the indications and labeling needed for over-the-counter use, supported by human factors testing, which checks whether people can use a device correctly from its labeling.[1]

Who it is for

The cleared indications cover persons 22 years or older who are not on insulin.[1] Biolinq said the device gives glucose range information to support general awareness of glucose patterns and trends.[2] The company also said Shine is not intended to provide glucose numbers for acute medical decisions such as insulin dosing or medication changes.[2] The FDA labeling makes a similar point: users are not meant to take medical action based on the device output without talking to a qualified healthcare professional.[1]

How it shows glucose

Shine does not show a number on the sensor. It uses a colored light instead. Here's what we found in the 510(k) summary: a blue light means glucose between 70 and 180 mg/dL, yellow means 181 to 400 mg/dL, and red means below 70 mg/dL.[1] Other light patterns flag a fast rise toward the yellow zone or a system error. A purple light means the sensor has reached the end of its life and should be replaced.[1]

The summary describes seven tiny electrodes that sit in the upper dermis, the skin layer just under the surface, on the inner forearm, worn where the user can see the light.[1] The device starts on its own, begins giving readings two hours after it goes on, needs no fingerstick calibration and stores data for up to five days.[1] An app is available but not required; the FDA indications say it gives more detailed glucose information and relates it to meals, rest and activity.[1]

Biolinq described the sensor as needle-free, saying its microsensors sit close to the skin's surface without a needle for placement.[2] The company also called Shine the first glucose sensor with a built-in primary display that works with and without a phone.[2] Those are the company's descriptions; the FDA documents we read do not use either phrase.

What this means for you

The FDA cleared Biolinq Shine for over-the-counter use by adults 22 and older who are not on insulin.[1] Biolinq said it shows glucose ranges, not numbers, and is not meant for insulin dosing or medication changes.[2] The September 24 release did not give a price or a date when people could buy it. If you use insulin, or you are weighing whether a range-only sensor fits your needs, talk to your care team or pharmacist.